Full Schedule

17 results found

Type here to filter the list

Thursday, September 21, 2023
8:00 AM - 8:15 AM ET
Welcome
Co-Chair: Edward B. Garon, MD, MS – University of California, Los Angeles
Co-Chair: Corey J. Langer, MD, FACP – Abramson Cancer Center, Hospital of the University of Pennsylvania
8:15 AM - 9:00 AM ET
Session 1: Birdseye View of the Current Tretatment Landscape in Metastatic NSCLC without Actionable Mutations
Presenter: Karen Reckamp, MD – Cedars Sinai Medical Center
9:00 AM - 9:45 AM ET
Session 2: Sensitizing and Atypical EGFR Mutations
Presenter: Gregory J. Riely, MD, PhD – Memorial Sloan Kettering Cancer Center
9:45 AM - 9:50 AM ET
Break
9:50 AM - 10:50 AM ET
Non-CME Innovation Theater - Sponsored by AstraZeneca
10:50 AM - 11:00 AM ET
Exhibit Hall
11:00 AM - 11:45 AM ET
Session 3: EGFR: The Challenge of Primary and Secondary Resistance
Presenter: Helena Yu, MD – Memorial Sloan Kettering Cancer Center
11:45 AM - 12:00 PM ET
Session 4: Debate: Alectinib vs Lorlatinib in ALK Positive - Lorlatinib
Debate Speaker: Misako Nagasaka, MD, PhD – University of California Irvine
12:00 PM - 12:15 PM ET
Session 4: Debate: Alectinib vs Lorlatinib in ALK Positive - Alectinib
Debate Speaker: Ticiana Leal, MD – Emory University
12:15 PM - 12:30 PM ET
Q&A Panel
Panelist: Ticiana Leal, MD – Emory University
Panelist: Misako Nagasaka, MD, PhD – University of California Irvine
12:30 PM - 12:35 PM ET
Break
12:35 PM - 1:35 PM ET
Non-CME Innovation Theater - Sponsored by Sanofi
1:35 PM - 2:20 PM ET
Session 5: Unique Immune Combinations with CPIs
Presenter: Hossein Borghaei, DO, MS – Fox Chase Cancer Center
2:20 PM - 3:05 PM ET
Session 6: Advancing the Management of NSCLC: A Focus on Emerging Therapies
Presenter: Ticiana Leal, MD – Emory University
3:05 PM - 3:35 PM ET
Exhibit Hall
3:35 PM - 4:20 PM ET
Session 7: The Era of ADCs in the Treatment of NSCLC Part 1: Class Overview and Specifics of TROP2, HER3, c-MET, and CEACAM5 Investigational ADCs
Presenter: Barbara Melosky, MD – Bc Cancer
4:20 PM - 5:05 PM ET
Session 8: HER2 and the Emerging Roles of HER Family ADCs
Presenter: Helen J. Ross, MD – Rush University